ScripBayer’s hopes of catching up with Boehringer Ingelheim’s small molecule HER2 inhibitor zongertinib have been boosted by regulators in the US putting sevabertinib, its same-class candidate for lung can
ScripWhile significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has seen fewer advances and patients continue to have limited treatment o
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Quiver, QurAlis To Combine Tech Platfor
ScripAs a privately held and family-owned pharma firm, Boehringer Ingelheim has more freedom to dance to its own tune than most of its peers, but it has still been candid about the scale of its aspirations